Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 406

1.

Community analysis and co-occurrence patterns in airway microbial communities during health and disease.

Einarsson GG, Zhao J, LiPuma JJ, Downey DG, Tunney MM, Elborn JS.

ERJ Open Res. 2019 Jul 8;5(3). pii: 00128-2017. doi: 10.1183/23120541.00128-2017. eCollection 2019 Jul.

2.

Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.

Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T; European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF’, Amaral MD, de Boeck K, Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T.

J Cyst Fibros. 2019 Jul 11. pii: S1569-1993(19)30815-X. doi: 10.1016/j.jcf.2019.06.011. [Epub ahead of print]

PMID:
31303382
3.

Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis.

Drevinek P, Pressler T, Cipolli M, De Boeck K, Schwarz C, Bouisset F, Boff M, Henig N, Paquette-Lamontagne N, Montgomery S, Perquin J, Tomkinson N, den Hollander W, Elborn JS.

J Cyst Fibros. 2019 Jun 7. pii: S1569-1993(19)30766-0. doi: 10.1016/j.jcf.2019.05.014. [Epub ahead of print]

4.

Draft Genome Sequence of Haemophilus haemolyticus Strain 16/010 O, Isolated from a Sputum Sample from a Cystic Fibrosis Patient.

Fluit AC, Bayjanov JR, Tunney M, Elborn JS, Rogers MRC, Schürch AC, Ekkelenkamp MB.

Microbiol Resour Announc. 2019 Jun 6;8(23). pii: e00243-19. doi: 10.1128/MRA.00243-19.

5.

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.

Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P; Antimicrobial Resistance International Working Group in Cystic Fibrosis.

Clin Infect Dis. 2019 May 6. pii: ciz364. doi: 10.1093/cid/ciz364. [Epub ahead of print]

PMID:
31056660
6.

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.

Bell SC, Barry PJ, De Boeck K, Drevinek P, Elborn JS, Plant BJ, Minić P, Van Braeckel E, Verhulst S, Muller K, Kanters D, Bellaire S, de Kock H, Geller DE, Conrath K, Van de Steen O, van der Ent K.

J Cyst Fibros. 2019 May 2. pii: S1569-1993(19)30073-6. doi: 10.1016/j.jcf.2019.04.014. [Epub ahead of print]

7.

Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis.

Liou TG, Adler FR, Argel N, Asfour F, Brown PS, Chatfield BA, Daines CL, Durham D, Francis JA, Glover B, Heynekamp T, Hoidal JR, Jensen JL, Keogh R, Kopecky CM, Lechtzin N, Li Y, Lysinger J, Molina O, Nakamura C, Packer KA, Poch KR, Quittner AL, Radford P, Redway AJ, Sagel SD, Sprandel S, Taylor-Cousar JL, Vroom JB, Yoshikawa R, Clancy JP, Elborn JS, Olivier KN, Cox DR.

BMC Med Res Methodol. 2019 Apr 26;19(1):88. doi: 10.1186/s12874-019-0705-0.

8.

Using registries for research in CF. How can we be sure about the outputs?

Elborn JS, Gonska T.

J Cyst Fibros. 2019 May;18(3):309-310. doi: 10.1016/j.jcf.2019.04.003. Epub 2019 Apr 11. No abstract available.

PMID:
30982754
9.

Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.

Sherrard LJ, Einarsson GG, Johnston E, O'Neill K, McIlreavey L, McGrath SJ, Gilpin DF, Downey DG, Reid A, McElvaney NG, Boucher RC, Muhlebach MS, Elborn JS, Tunney MM.

J Cyst Fibros. 2019 Mar 21. pii: S1569-1993(19)30052-9. doi: 10.1016/j.jcf.2019.02.012. [Epub ahead of print]

PMID:
30905581
10.

New insights into immunological responses to infection in bronchiectasis.

Shteinberg M, Shah A, Elborn JS.

Eur Respir J. 2019 Feb 7;53(2). pii: 1802395. doi: 10.1183/13993003.02395-2018. Print 2019 Feb. No abstract available.

PMID:
30759421
11.

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR; Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group.

J Cyst Fibros. 2019 Mar;18(2):236-243. doi: 10.1016/j.jcf.2019.01.008. Epub 2019 Jan 30.

PMID:
30709744
12.

British Thoracic Society guideline for bronchiectasis in adults.

Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn JS, Floto RA, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, Hiscocks E, Hurst JR, Johnson C, Kelleher WP, Bedi P, Payne K, Saleh H, Screaton NJ, Smith M, Tunney M, Whitters D, Wilson R, Loebinger MR.

BMJ Open Respir Res. 2018 Dec 28;5(1):e000348. doi: 10.1136/bmjresp-2018-000348. eCollection 2018.

13.

Clinical Research Fellow.

Addy C, Bradley J, McGarvey L, Elborn JS, Downey D.

Ulster Med J. 2019 Jan;88(1):60-61. Epub 2019 Jan 22. No abstract available.

14.

Adults with cystic fibrosis and pulmonologists: new training needed to recruit future specialists.

Blasi F, Elborn JS, Palange P.

Eur Respir J. 2019 Jan 17;53(1). pii: 1802209. doi: 10.1183/13993003.02209-2018. Print 2019 Jan. No abstract available.

PMID:
30655450
15.

Targeting of cathepsin S reduces cystic fibrosis-like lung disease.

Small DM, Brown RR, Doherty DF, Abladey A, Zhou-Suckow Z, Delaney RJ, Kerrigan L, Dougan CM, Borensztajn KS, Holsinger L, Booth R, Scott CJ, López-Campos G, Elborn JS, Mall MA, Weldon S, Taggart CC.

Eur Respir J. 2019 Mar 28;53(3). pii: 1801523. doi: 10.1183/13993003.01523-2018. Print 2019 Mar.

PMID:
30655278
16.

Quality control for multiple breath washout tests in multicentre bronchiectasis studies: Experiences from the BRONCH-UK clinimetrics study.

O'Neill K, Lakshmipathy GR, Ferguson K, Cosgrove D, Hill AT, Loebinger MR, Carroll M, Chalmers JD, Gatheral T, Johnson C, DeSoyza A, Hurst JR, Bradbury I, Elborn JS, Bradley JM.

Respir Med. 2018 Dec;145:206-211. doi: 10.1016/j.rmed.2018.10.030. Epub 2018 Nov 1.

PMID:
30509710
17.

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.

Sermet-Gaudelus I, Clancy JP, Nichols DP, Nick JA, De Boeck K, Solomon GM, Mall MA, Bolognese J, Bouisset F, den Hollander W, Paquette-Lamontagne N, Tomkinson N, Henig N, Elborn JS, Rowe SM.

J Cyst Fibros. 2019 Jul;18(4):536-542. doi: 10.1016/j.jcf.2018.10.015. Epub 2018 Nov 19.

18.

Defining antimicrobial resistance in cystic fibrosis.

Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):696-704. doi: 10.1016/j.jcf.2018.08.014. Epub 2018 Sep 25. Review.

PMID:
30266518
19.

Activity of hypothiocyanite and lactoferrin (ALX-009) against respiratory cystic fibrosis pathogens in sputum.

Tunney MM, Payne JE, McGrath SJ, Einarsson GG, Ingram RJ, Gilpin DF, Juarez-Perez V, Elborn JS.

J Antimicrob Chemother. 2018 Dec 1;73(12):3391-3397. doi: 10.1093/jac/dky357.

PMID:
30219825
20.

Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention.

Bell SC, Elborn JS, Byrnes CA.

Respirology. 2018 Nov;23(11):1006-1022. doi: 10.1111/resp.13398. Epub 2018 Sep 11. Review.

21.

High prevalence of triazole resistance in clinical Aspergillus fumigatus isolates in a specialist cardiothoracic centre.

Abdolrasouli A, Scourfield A, Rhodes J, Shah A, Elborn JS, Fisher MC, Schelenz S, Armstrong-James D.

Int J Antimicrob Agents. 2018 Nov;52(5):637-642. doi: 10.1016/j.ijantimicag.2018.08.004. Epub 2018 Aug 10.

PMID:
30103005
22.

EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics.

Elborn JS, Ahuja S, Springman E, Mershon J, Grosswald R, Rowe SM.

Contemp Clin Trials. 2018 Sep;72:86-94. doi: 10.1016/j.cct.2018.07.014. Epub 2018 Jul 26.

23.

Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study.

Muhlebach MS, Hatch JE, Einarsson GG, McGrath SJ, Gilipin DF, Lavelle G, Mirkovic B, Murray MA, McNally P, Gotman N, Davis Thomas S, Wolfgang MC, Gilligan PH, McElvaney NG, Elborn JS, Boucher RC, Tunney MM.

Eur Respir J. 2018 Jul 11;52(1). pii: 1800242. doi: 10.1183/13993003.00242-2018. Print 2018 Jul.

24.

"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00193-18. doi: 10.1128/JCM.00193-18. Print 2018 Sep.

25.

INCREASING BURDEN OF ANTIMICROBIAL RESISTANCE IN PSEUDOMONAS AERUGINOSA FROM ADULT PATIENTS WITH CYSTIC FIBROSIS (CF) IN NORTHERN IRELAND: THEN AND NOW.

Gramegna A, Moore JE, McCaughan J, Millar BC, Ewing J, Elborn JS, Blasi F, Downey DG.

Ulster Med J. 2018 May;87(2):129-130. Epub 2018 May 30. No abstract available.

26.

Airway persistence by the emerging multi-azole-resistant Rasamsonia argillacea complex in cystic fibrosis.

Abdolrasouli A, Bercusson AC, Rhodes JL, Hagen F, Buil JB, Tang AYY, de Boer LL, Shah A, Milburn AJ, Elborn JS, Jones AL, Meis JF, Fisher MC, Schelenz S, Simmonds NJ, Armstrong-James D.

Mycoses. 2018 Sep;61(9):665-673. doi: 10.1111/myc.12789. Epub 2018 Jun 20.

27.

Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination.

McShane PJ, Weers JG, Tarara TE, Haynes A, Durbha P, Miller DP, Mundry T, Operschall E, Elborn JS.

Pulm Pharmacol Ther. 2018 Jun;50:72-79. doi: 10.1016/j.pupt.2018.03.005. Epub 2018 Apr 3. Review.

28.

In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.

Gramegna A, Millar BC, Blasi F, Elborn JS, Downey DG, Moore JE.

J Glob Antimicrob Resist. 2018 Sep;14:224-227. doi: 10.1016/j.jgar.2018.03.002. Epub 2018 Mar 17.

PMID:
29559421
29.

CFTR Modulators: Deciding What Is Best for Individuals in an Era of Precision Medicine.

Elborn JS.

Ann Am Thorac Soc. 2018 Mar;15(3):298-300. doi: 10.1513/AnnalsATS.201712-951ED. No abstract available.

PMID:
29493341
30.

Cystic fibrosis epithelial cells are primed for apoptosis as a result of increased Fas (CD95).

Chen Q, Pandi SPS, Kerrigan L, McElvaney NG, Greene CM, Elborn JS, Taggart CC, Weldon S.

J Cyst Fibros. 2018 Sep;17(5):616-623. doi: 10.1016/j.jcf.2018.01.010. Epub 2018 Mar 2.

PMID:
29486923
31.

The use of high-throughput sequencing to investigate an outbreak of glycopeptide-resistant Enterococcus faecium with a novel quinupristin-dalfopristin resistance mechanism.

Shaw TD, Fairley DJ, Schneiders T, Pathiraja M, Hill RLR, Werner G, Elborn JS, McMullan R.

Eur J Clin Microbiol Infect Dis. 2018 May;37(5):959-967. doi: 10.1007/s10096-018-3214-x. Epub 2018 Feb 24.

32.

Airway infection, systemic inflammation and lung clearance index in children and adults with cystic fibrosis.

O'Neill K, Bradley JM, Reid A, Downey DG, Rendall J, McCaughan J, Moore JE, Tunney MM, Elborn JS.

Eur Respir J. 2018 Jan 31;51(2). pii: 1701704. doi: 10.1183/13993003.01704-2017. Print 2018 Feb. No abstract available.

PMID:
29386349
33.

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702053. doi: 10.1183/13993003.02053-2017. Print 2018 Jan.

PMID:
29371384
34.

RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

De Soyza A, Aksamit T, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702052. doi: 10.1183/13993003.02052-2017. Print 2018 Jan.

PMID:
29371383
35.

Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network.

Chalmers JD, Ringshausen FC, Harris B, Elborn JS, Posthumus A, Haworth CS, Pilkington N, Polverino E, Ruddy T, Aliberti S, Goeminne PC, Winstanley C, De Soyza A.

Eur Respir J. 2018 Jan 11;51(1). pii: 1701937. doi: 10.1183/13993003.01937-2017. Print 2018 Jan. Review. No abstract available.

36.

Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD.

Dicker AJ, Crichton ML, Cassidy AJ, Brady G, Hapca A, Tavendale R, Einarsson GG, Furrie E, Elborn JS, Schembri S, Marshall SE, Palmer CNA, Chalmers JD.

Thorax. 2018 Jun;73(6):510-518. doi: 10.1136/thoraxjnl-2016-209931. Epub 2017 Nov 3.

37.

Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS.

N Engl J Med. 2017 Nov 23;377(21):2013-2023. doi: 10.1056/NEJMoa1709846. Epub 2017 Nov 3.

38.

CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.

Ronan NJ, Einarsson GG, Twomey M, Mooney D, Mullane D, NiChroinin M, O'Callaghan G, Shanahan F, Murphy DM, O'Connor OJ, Shortt CA, Tunney MM, Eustace JA, Maher MM, Elborn JS, Plant BJ.

Chest. 2018 Feb;153(2):395-403. doi: 10.1016/j.chest.2017.10.005. Epub 2017 Oct 14.

PMID:
29037527
39.

Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.

Elborn JS, Davies J.

Lancet Respir Med. 2017 Sep;5(9):681-683. doi: 10.1016/S2213-2600(17)30311-9. No abstract available.

PMID:
28853396
40.

Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His.

Shteinberg M, Downey DG, Beattie D, McCaughan J, Reid A, Stein N, Elborn JS.

ERJ Open Res. 2017 Mar 31;3(1). pii: 00056-2016. doi: 10.1183/23120541.00056-2016. eCollection 2017 Jan.

41.

Training in multiple breath washout testing for respiratory physiotherapists.

O'Neill K, Elborn JS, Tunney MM, O'Neill P, Rowan S, Martin S, Bradley JM.

Physiotherapy. 2018 Mar;104(1):61-66. doi: 10.1016/j.physio.2017.04.003. Epub 2017 Apr 25.

PMID:
28822601
42.

Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis.

Burgel PR, Bellis G, Elborn JS.

Eur Respir J. 2017 Aug 3;50(2). pii: 1700763. doi: 10.1183/13993003.00763-2017. Print 2017 Aug. No abstract available.

43.

Characterisation of eppin function: expression and activity in the lung.

Scott A, Glasgow A, Small D, Carlile S, McCrudden M, McLean D, Brown R, Doherty D, Lundy FT, Hamid UI, O'Kane CM, McAuley DF, Brodlie M, Tunney M, Elborn JS, Irwin CR, Timson DJ, Taggart CC, Weldon S.

Eur Respir J. 2017 Jul 13;50(1). pii: 1601937. doi: 10.1183/13993003.01937-2016. Print 2017 Jul.

44.

Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with Pseudomonas aeruginosa.

Pattison SH, Gibson DS, Johnston E, Peacock S, Rivera K, Tunney MM, Pappin DJ, Elborn JS.

Eur Respir J. 2017 Jul 5;50(1). pii: 1601569. doi: 10.1183/13993003.01569-2016. Print 2017 Jul.

45.

Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens.

Payne JE, Dubois AV, Ingram RJ, Weldon S, Taggart CC, Elborn JS, Tunney MM.

Int J Antimicrob Agents. 2017 Sep;50(3):427-435. doi: 10.1016/j.ijantimicag.2017.04.014. Epub 2017 Jun 27.

PMID:
28666755
46.

Evidence of persistence of Prevotella spp. in the cystic fibrosis lung.

Gilpin DF, Nixon KA, Bull M, McGrath SJ, Sherrard L, Rolain JM, Mahenthiralingam E, Elborn JS, Tunney MM.

J Med Microbiol. 2017 Jun 13. doi: 10.1099/jmm.0.000500. [Epub ahead of print]

PMID:
28604331
47.

Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.

Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T; EMBARC/BRR definitions working group.

Eur Respir J. 2017 Jun 8;49(6). pii: 1700051. doi: 10.1183/13993003.00051-2017. Print 2017 Jun.

48.

Current and emerging comorbidities in cystic fibrosis.

Ronan NJ, Elborn JS, Plant BJ.

Presse Med. 2017 Jun;46(6 Pt 2):e125-e138. doi: 10.1016/j.lpm.2017.05.011. Epub 2017 May 27. Review.

PMID:
28554721
49.

The effect of increased fruit and vegetable consumption on selected macronutrient and micronutrient intakes in four randomised-controlled trials.

Fulton SL, McKinley MC, Neville CE, Baldrick FR, Mulligan C, McCall DO, McCance DR, Edgar JD, Elborn JS, Young IS, Patterson CC, Woodside JV.

Br J Nutr. 2017 May;117(9):1270-1278. doi: 10.1017/S0007114517001088. Epub 2017 May 24.

PMID:
28535825
50.

Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients.

Mustafa MH, Khandekar S, Tunney MM, Elborn JS, Kahl BC, Denis O, Plésiat P, Traore H, Tulkens PM, Vanderbist F, Van Bambeke F.

Eur Respir J. 2017 May 19;49(5). pii: 1601847. doi: 10.1183/13993003.01847-2016. Print 2017 May.

Supplemental Content

Loading ...
Support Center